Fluoxymesterone
Other name：Halotestin
CAS register number：76-43-7
EINECS：200-961-8
Formulae hypotheticae：C20H29FO3
M. pondus：336.44
Point liquescens：240 °C
Assay：97.0~103.0%
Usage：Treating a deficiency of the male hormone testosterone when the body does not make enough. used to stimulate puberty in males with delayed puberty. Treating advanced breast cancer in women who are 1 to 5 years past menopause.
Fluoxymesterone synthetica derivatio Testosterone, sed specialiter derivativa Methyltestosteronis (Testosterone quod est Methylated).
Vulgo existimatur steroidem anabolicum fortissimum oralem quae in Estrogen aromatizare non potest et etiam validissimas vires androgenicas pariter ostendit..
Effects
maintenance and gaining of lean mass and tissue repair following various conditions of trauma (burns, bone fractures, malnutrition, muscle-wasting diseases, treatment of paraplegics, and as an adjunct to chronic administration of corticosteroids).
Males its use was indicated for the treatment of insufficient androgen production (hypogonadism or andropause).
In females, Halo would be approved for use in treating chronic dysfunctional uterine bleeding as well as female breast cancer.
Halotestin will exert performance enhancing benefits without the unwanted increases in weight that may slow down an athlete, such as a sprinter, who requires the least weight as possible in order to maximize speed efficiency while still receiving that benefit of performance enhancement.
